Variations in gene expression and response to neoadjuvant chemotherapy in breast carcinoma.
Cancer Invest
; 27(5): 521-8, 2009 Jun.
Article
en En
| MEDLINE
| ID: mdl-19479487
ABSTRACT
In this study, we performed a screening of 266 gene expressions in breast carcinomas and carried out correlations with histological response to either FEC-100 (fluorouracil-epirubicin-cyclophosphamide; n = 16) or Tax-Epi (docetaxel-epirubicin; n = 12) treatment. Gene expression in biopsies obtained before and after one course of chemotherapy was analyzed. Expression of specific genes was significantly changed after one course of chemotherapy, particularly for Tax-Epi treatment. Comparison with histological response for both treatments revealed that only good responders exhibited changes in gene-expression profile. These results agree that expression of different genes changes in response to anthracycline-based neoadjuvant chemotherapy and show, for the first time, that response to docetaxel-based treatment implied also changes in gene-expression profile.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias de la Mama
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Biomarcadores de Tumor
/
Terapia Neoadyuvante
/
Perfilación de la Expresión Génica
Tipo de estudio:
Clinical_trials
Límite:
Female
/
Humans
Idioma:
En
Año:
2009
Tipo del documento:
Article